Reforgene approved as a postdoctoral research workstation sub-station

Recently, Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") received a notice from the Office of the National Postdoctoral Management Committee approving the establishment of a postdoctoral research workstation sub-station. This achievement marks a new breakthrough for Reforgene in attracting and cultivating high-level talent and in industry-research integration, injecting strong talent momentum into the company's continuous development of globally competitive innovative gene editing medicines.

Reforgene is a leading technology innovation enterprise in China's biomedical field, focused on the R&D and translational application of gene editing technology, deeply cultivating innovation in curative medicines for major diseases, continuously advancing core technology breakthroughs, building international competitiveness in the gene editing technology field, and forming a complete R&D system and professional technical team covering "early discovery, preclinical development and clinical trials". The approval of this postdoctoral research workstation fully reflects the company's comprehensive strength in gene editing technology and product accumulation, full-chain R&D system construction, and high-level talent echelon building.

In terms of research platforms and talent development, Reforgene has gradually built a high-level R&D team exploring gene editing for the treatment of major diseases, and has successively undertaken major research projects such as the Guangdong Provincial Key R&D Program and the National Key R&D Program. Relying on the postdoctoral research workstation sub-station as a high-level innovation platform, Reforgene will further deepen industry-academia-research-medicine collaboration, focus on key technologies, and build a top talent echelon through the combined approach of attraction and cultivation. The company will continue to enhance its core competitiveness, accelerate the R&D and implementation of innovative gene editing medicines, contribute more innovative achievements to the high-quality development of the biomedical industry, illuminate more patients' paths to new life, and strive to grow into a leading gene editing technology enterprise with international influence.